Unaudited Financial Results for the quarter ended June 30, 2025

Pharmaids Pharmaceuticals reported a sharply wider loss in Q1 FY26 despite strong revenue growth. On a consolidated basis, revenue from operations rose to Rs 666.36 lakhs from Rs 473.07 lakhs in the year-ago quarter, a growth of about 41%. However, total expenses surged to Rs 1,387.49 lakhs (from Rs 896.50 lakhs), driven by higher employee costs, finance costs, and other expenses. Consolidated net loss widened to Rs 531.53 lakhs (from Rs 312.45 lakhs), and standalone net loss ballooned to Rs 436.30 lakhs (from Rs 162.34 lakhs). The auditor issued a clean limited review report with an Emphasis of Matter on the post-quarter disinvestment of the company's 66.50% stake in Anugraha Chemicals, subject to shareholder approval via postal ballot. The company is a contract research and manufacturing services (CRAMS) player, and losses continue to erode its equity base (other equity of Rs 2,405.25 lakhs on consolidated books).